Tirzepatide Frequently Asked Questions

Tirzepatide is a synthetic peptide that acts as a dual agonist on both the GIP and GLP-1 receptors. This dual mechanism is unique among metabolic peptides. ORYN's Tirzepatide pen contains 10 mg at >99% purity.

Tirzepatide simultaneously activates GIP and GLP-1 receptors involved in insulin secretion, glucose metabolism, appetite regulation, and gastric emptying. The dual-agonist mechanism produces synergistic metabolic effects beyond what single-receptor agonists achieve.

Studied in research related to metabolic function, body weight regulation, insulin sensitivity, blood glucose control, appetite physiology, and cardiovascular metabolic health. Subject of the SURPASS and SURMOUNT clinical trial programmes.

ORYN Tirzepatide is available in a pre-mixed pen containing 10 mg in 3 mL. Designed for subcutaneous injection with click-based dosing. No manual reconstitution required. 30-day pen format for consistent daily dosing.

Manufactured to >99% purity in GMP-certified facilities. Each batch undergoes rigorous third-party HPLC and mass spectrometry analysis. CoAs available for all batches.

Store refrigerated at 2-8°C, protected from direct light. Do not freeze. Shelf life is 24 months under proper conditions.

Due to Tirzepatide's potent dual-receptor mechanism, it is typically studied as a standalone compound. Researchers should review published literature on potential interactions. Research information only.

Each ORYN Tirzepatide pen is designed for a 30-day dosing protocol. The 10 mg / 3 mL formulation delivers precise daily doses over the complete monthly period.

The Tirzepatide Peptide Pen contains 10 mg for daily administration over 30 days. The MediT Pen is a prefilled single-use pen containing 40 mg for once-weekly administration.

Available for research purchase in the UK. Tirzepatide is a research compound when supplied outside of prescribed medical contexts. ORYN supplies strictly for research and laboratory use.